GIPERGOMOSISTEINEMIYASI BO‘LGAN BEMORLARDA YURAK ISHEMIK KASALLIGINI KECHISH XUSUSIYATLARI
Article Sidebar
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Main Article Content
Аннотация:
Yurak ishemik kasalligi (YuIK) butun dunyo bo'ylab salomatlik uchun jiddiy muammo bo'lib, uning patogeneziga turli xil xavf omillari yotadi. Ular orasida gipergomosisteinemiya potentsial o'zgartirilishi mumkin bo'lgan xavf omili sifatida paydo bo'ldi, bu e'tiborni talab qiladi. Ushbu maqola gipergomosisteinemiya bilan og'rigan bemorlarda YuIK ning xususiyatlarini o'rganib, uning epidemiologik ahamiyati, patofiziologik mexanizmlari va klinik oqibatlariga e'tibor qaratadi. Sharh gomosistein darajasining ko'tarilishi ateroskleroz va trombozni qanday qilib koronar arteriya kasalligi va miokard infarktiga olib kelishi mumkinligini tushuntirish uchun joriy adabiyotlarni sintez qiladi. Bundan tashqari, u gipergomosisteinemiyasi bo'lgan odamlarda YuIKni boshqarish uchun mo'ljallangan diagnostika muammolari va terapevtik strategiyalarni muhokama qiladi. Ushbu jihatlarni tushunish gomosistein darajasining oshishi bilan bog'liq YuIK global yukini kamaytirishga qaratilgan profilaktika choralari va davolash strategiyalarini optimallashtirish uchun juda muhimdir.
Article Details
Как цитировать:
Библиографические ссылки:
Brattstrom L, Israelsson B, Olsson A et al. Plasma homocysteine in women on oral oestrogenFcontaining contraceptives and in men with oestrogenFtreated prostatic carcinoma// Scand J Clin Lab Investig 52: 283F287
Brattstrom L, Landgren F, Israelsson B et al. (1998a) Lowering blood homocysteine with folic acidbased supplements: metaFanalyF sis of randomised trials. Br Med J 316: 894F898
Grubben MJ, Boers GH, Blom HJ, Broekhuizen R, de Jong R, van Rijt J, de Ruijter E, Swinkels DW, Nagengast FM and Katan MB (2000) Unfiltered coffee increases plasma homocysteine concentraF tions in healthy volunteers: a randomized trial. Am J Clin Nutr 71: 480F484 32. 4.
Hackam DG, Peterson JC and Spence JD (2000) What level of plasF ma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 micromol/L. Am J Hypertens 13: 105F110
Herrmann W, Obeid R. Hyperhomocysteinemia: a critical review of old and new aspects. Curr Drug Metab. 2011;12(1):1-11.
Usmanov MM, Chimed-Ochir O, Batkhorol B, Yumiya Y, Hujamberdieva LM, Kubo T. Obesity, Burden of Ischemic Heart Diseases and Their Ecological Association: The Case of Uzbekistan. Int J Environ Res Public Health. 2022 Aug 22;19(16):10447. doi: 10.3390/ijerph191610447. PMID: 36012082; PMCID: PMC9408059.
Котельников М.В. Гипергомоцистеинемия: мост от теории к практике в лечении тромбофилий // Кардиология.F 2004.F №10. – с. 102F106.
Кули Д.А. Сердечно – сосудистые заболевания; устранение факторов риска и другие профилактические мероприятия // Междунар. мед. ж. – 1999.F №1.F с.15F19.
Лысенко М.Э. Коррекция гипергомоцистеинемии у больных ИБС // Украинский терапевтический журнал.F 2004.F №1.F с.69F73.
Nygard O, Refsum H, Ueland PM, Stensvold I, Nordrehaug JE, Kvale G and Vollset SE (1997b) Coffee consumption and plasma total homocysteine: the Hordaland Homocysteine study. Am J Clin Nutr 65: 136F143
Schwaninger M, Ringleb P, Winter R, Kohl B, Fiehn W, Rieser PA and WalterFSack I (1999) Elevated plasma concentrations of homoF cysteine in antiepileptic drug treatment. Epilepsia 40: 345F350
Stanger O, Fowler B, Piertzik K, et al. Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendations. Expert Rev Neurother. 2009;9(9):1393-1412.
Tyagi N, Sedoris KC, Steed M, et al. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol. 2005;289(1):H264-273
Ubbink JB, van der MA, Delport R, Allen RH, Stabler SP, Riezler R and Vermaak WJ (1996) The effect of a subnormal vitamin BF6 status on homocysteine metabolism. J Clin Investig 98: 177F184
Ueland PM and Refsum H (1989) Plasma homocysteine, a risk facF tor for vascular disease: plasma levels in health, disease and drug therapy. J Lab Clin Med 114: 473F501
Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA and Rabelink TJ (1998) 5Fmethyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesF terolemia. Circulation 97: 237F241
Vermeulen EGJ, Stehouwer CDA, Twisk JWR, et al. Effect of homocysteine Flowering treatment with folic acid plus vitamin BF6 on progression of subclinical atherosclerosis: a randomised, placeF boFcontrolled trial.// Lancet 2000F 355: 517F522